medication of all patients and 1 hour after that echocardiograpdic parameters was measured again, and the results were compared. RESULTS: Peak pulmonary artery pressure and pulmonary acceleration time (PAT) significantly improved 1 hour after 100 mg oral single dose of Sildenafil (p < 0.005, 95% CI 5.41-22.93 and p = 0.005 95% CI -12.89-2.95 respectively). In addition although the right heart dimensions (right atrium & ventricle) showed a trend toward improvement, but were not statistically significant (p = 0.135, p = 0.08 respectively). CONCLUSION: These results suggest that Sildenafil has a acute significant improvement effect on PAP and PAT in patients with PPH. OBJECTIVES: Community Acquired Pneumonia (CAP) is a leading cause of hospitalisation and mortality in industrialised countries. This study was an economic evaluation comparing moxifloxacin with a combination of levofloxacin plus ceftriaxone in patients hospitalised with CAP in Germany. METHODS: The MOTIV trial was a multinational, prospective, randomized, double-blind study in adults with CAP requiring hospitalisation and parenteral antibiotic therapy. Patients were randomised to either moxifloxacin (N = 368), or levofloxacin plus ceftriaxone (N = 365) and received sequential treatment with intravenous followed by oral antibiotics for 7-14 days. The primary effectiveness endpoint was clinical response 5-7 days after completion of treatment. Resource use recorded included length of stay, ward type, investigations and procedures performed and dose and frequency of study drug used. Costs were calculated from a German hospital perspective, drug costs were taken from the Rote Liste and other costs from a recent publication. A stochastic sensitivity analysis was performed. RESULTS: Mean age was 65 years (range 18-101) and 58% of patients had severe CAP. The percentage of patients reporting clinical response (moxifloxacin: 80%, comparator: 84%) met criteria for clinical equivalence so a cost-minimisation analysis was performed. Mean per patient cost was €2190 (95% CI: €1954, €2463) for the moxifloxacin group, and €2619 (95% CI: €2422, €2832) for the comparator group, difference (-€430, 95% CI: -€740, -€138). Medication costs were significantly lower for moxifloxacin than comparator (-€470, 95% CI: -€522, -€421) but accounted for only 15-30% of total costs. Subgroup analysis of patients with COPD, cardiovascular disease, microbiologically proven pneumonia, or severe CAP at baseline produced consistent findings. Average cost was sensitive to price paid for study drugs and the daily cost of hospital stay. CONCLUSION: Treatment with moxifloxacin was significantly less costly than treatment with levofloxacin plus ceftriaxone, with no clinically significant difference in outcomes achieved.
worldwide. The objectives of this study were to measure the societal costs of COPD including both direct and indirect costs, and to estimate the costs for different severity grades of disease according to changed Swedish guidelines. METHODS: A welldefined and representative cohort of subjects was used to examine the costs of COPD. Regular telephone interviews were done with 212 subjects derived from the OLIN-Studies in northern Sweden. The severity grades of COPD were divided according to changed Swedish guidelines, and furthermore Mild COPD (FEV1 50-79% of predicted) was divided into three sub-groups, Mild I, II and III. RESULTS: A positive relationship was found between costs and severity grades of COPD, patients with lower FEV1 % of predicted normal being significantly more expensive. Furthermore, the total costs differed significantly between the Mild and Pre-clinical severity groups, from a mean value of SEK 2,513 per subject in the Pre-clinical group to SEK 28,463 for subjects having FEV1 50-59% of predicted. The same pattern was found both in direct and indirect costs. Costs for medicines and hospitalisations increased significantly according to FEV1 values in the Mild and Preclinical groups of disease. Costs for disability pension among indirect costs showed a similar trend. The annual total costs for Severe (FEV1 < 30% of predicted), Moderate (30-49%), Mild I (50-59%), Mild II (60-69%), Mild III (70-79%), and Preclinical COPD (>79%) were SEK 183, 474, 70, 609, 28, 463, 11, 527, 6, 287 and 2, 513, respectively . CONCLUSION: Large variations were found in both the level and breakdown of costs for COPD, mainly depending on the severity of the disease. When dividing mild COPD into three different severity grades of disease, we also found a positive relationship between costs and severity of disease.
PRS4 RELATIONSHIP BETWEEN TIME OF DURATION OF COPD AND FREQUENCY OF DISEASE EXACERBATIONS
Jahnz-Rozyk K, Targowski T, From S Military Institute of Health Service, Warsaw, Poland OBJECTIVES: Assessment of the influence of nicotine addiction, time of duration and severity of COPD on the frequency of exacerbations. METHODS: 71 patients with moderate-tosevere COPD (30 with moderate and 41 with severe) were enrolled to the study. The smoking status, FEV1 value, time of duration of COPD, and a one-year history of incidence of exacerbations were assessed in all the subjects. The relationship between the number of exacerbations and the studied features was evaluated with the regression model. RESULTS: Thirteen (18.3%) subjects were current smokers, 9 (12.7%) had never smoked and 50 (70%) had smoked in the past. The mean intensity of cigarette smoking amounted to 34.7 pack-years [CI: 28.7-40.7]. The mean time of COPD duration was 9.2 [CI: 7.7-10.8] years, the mean frequency of exacerbation-3.1 [CI: 2.5-3.6] per year, and the mean % value of FEV1 was 48.1% [CI: 43.7-52.5]. There was no significant relationship between the frequency of exacerbations and the number of pack-years, smoking status, % value of FEV1 and severity of COPD. A significant correlation was observed between the time of duration of COPD and average number of exacerbations (r = 0.31, p = 0.009). It was calculated that each successive year of COPD duration is associated with 3% accumulation of exacerbation risk (determination coefficient-R2 = 0.03). CON-CLUSION: Long-time duration of COPD is related to a significant increase of the risk of COPD exacerbations-the key drivers in the overall costs of the disease. The aim of the study was to estimate the economic impact of improved pharmaceutical care in obstructive airway diseases (OAD) by evaluating the effects of the introduction of new pharmaceutical treatments in the costs of OAD treatment between 1996 and 2005. METHODS: To analyse the real change in the costs of OAD treatment, we estimated costs in 2005 assuming that the treatment practices (pharmaceuticals, hospitalizations, outpatient visits) had been similar to 1996 and subsequently compared these expected costs to the actual costs in 2005. The change in real costs due to improved pharmaceutical care was estimated by evaluating the change in the number of exacerbations requiring treatment. A spreadsheet based probabilistic simulation model was used. The data on health care resources, pharmaceuticals and costs were obtained from national registries. The effectiveness of pharmaceutical treatments in reducing exacerbations was obtained from three published meta-analyses. RESULTS: Compared to 1996, the improved pharmaceutical treatment decreased other OAD treatment costs in 2005 by 33.7 (95% CI: 19.4-50.9) million euros explaining 42.1% of the decrease in secondary health care costs of OAD in Finland. When adjusting for the increase in the number of patients, the extra costs of new pharmaceutical treatments were 5.1 million euros. Thus the increase in pharmaceutical costs was offset more than 6-fold by the reduction in the secondary health care costs. CONCLUSION: The OAD treatment costs in Finland have decreased significantly as a result of increased use of more effective pharmaceuticals. When pharmaceuticals are properly evaluated as one part of the treatment process, the expressed concerns over the increasing pharmaceutical costs seem to be unfounded in the case of OAD.
PRS6 ECONOMIC BURDEN OF DISEASE OF PULMONARY ARTERIAL HYPERTENSION IN GERMANY: AN INTERIM ANALYSIS OF RESOURCE UTILISATION
Ehlken B 1 , Plesnila Frank C 1 , Ghofrani HA 2 , Grimminger F 2 , Hoeper MM 3 , Stähler G 4 , Wilkens H 5 , Berger K 1 , Resch A 6 1 MERG-Medical Economics Research Group, München, Germany, 2 University Hospital Giessen and Marburg, Giessen, Germany, 3 Hannover Medical School, Hanover, Germany, 4 Klinik Löwenstein, Löwenstein, Germany, 5 University Hospitals of the Saarland, Homburg/Saar, Germany, 6 Pfizer Deutschland GmbH, Karlsruhe, Germany OBJECTIVES: To describe health care provision and resource consumption in patients with pulmonary arterial hypertension (PAH) in Germany. METHODS: A multi-centre, cross-sectional, retrospective and prospective study was conducted which addressed PAH care in hospitals and in the ambulant setting taking into account the patients' perspective. Study period covered 15 months. In hospitals, chart abstraction was accomplished 12 months retrospectively and 3 months prospectively. A GPs' questionnaire covered health care utilisation in the officebased sector and two patient questionnaires were applied to collect data on health status, resource consumption (over 3 months), and quality of life. RESULTS: Ten hospitals enrolled 150 patients with PAH; data of 118 patients (treated October 2004 -December 2006 were considered within this interim analysis. Response rate of GP questionnaire was 52%, of patient questionnaires 85% (1st questionnaire) and 76% (2nd questionnaire). Mean age of patients was 55 years (SD 14), 72% were female. 60% suffered from idiopathic PAH and 40% from PAH mainly associated with collagen vascular diseases (37%), congenital systemic-to-pulmonary shunts (26%), or portal hypertension (22%). Mean duration from occurrence of first symptoms until diagnosis was 2.3 years (SD 4.4) . Within 15 months mean number of GP visits was 23.1 (SD 16.2); mean number of hospital visits was 4.5. 44% of patients were hospitalised (mean length of stay: 7.1 days SD 6.1). Hospitalisation with surgical interventions (5% of hospital stays) occurred for port-transplantation or catheter replacement. 59% of patients received anticoagulants, 60% diuretics, 27% calciumantagonists, 66% endothelin-receptor antagonists, 20% inhalative prostacyclin analogues, and 25% PDE5 inhibitors. 10% of patients participated in rehabilitation with a mean length of stay of 30.1 days (SD 11.3) . CONCLUSION: This analysis is the first step in a comprehensive study on health care provision and economic burden of PAH in Germany. In a second step outcomes, e.g. disease severity and quality of life, will be assessed.
PRS7

ANALYSIS OF THE PREDICTIVE ABILITY OF DIAGNOSTIC COST GROUPS, RXGROUPS, AND PRIOR COST FOR TEXAS MEDICAID COPD PATIENTS
Yarger SA, Rascati KL, Leslie RC The University of Texas at Austin, Austin, TX, USA OBJECTIVES: The objective of this study was to test the ability of Diagnostic Cost Groups (DCGs), RxGroups, and prior cost risk models to identify high risk patients within the Texas Medicaid Chronic Obstructive Pulmonary Disease (COPD) population who could benefit from case management intervention. METHODS: DCGs, RxGroups, and prior cost risk models were used to predict future medical costs. ICD-9 diagnostic codes, NDC drug codes and 2001 total health care costs were input into the risk models. The study included Texas Medicaid patients under the age of 65 who had an inpatient diagnoses of COPD in 2000 and were continuously enrolled in Medicaid from 2000-2002 (n = 7967) . The risk models predicted total health care costs for 2002. Predicted costs were compared to actual 2002 costs using R 2 and mean absolute prediction error. Prediction of high cost cases were analyzed using the positive predictive value (PPV) of the top 5% of high cost patients. RESULTS: The R 2 was 0.035 for the DCG inpatient + RxGroups model and 0.033 for the prior cost model. For the top 5% of high cost patients the DCG + RxGroups model had a PPV of 20.5% (82/ 399). PPV for the prior cost model was 33.1%(132/399). The mean absolute prediction error was $7293 for the DCG inpatient + RxGroups model and $7429 for the prior cost model. CONCLUSION: Diagnosis-based risk adjustment models using only inpatient and pharmacy data may not be as useful as prior cost data when attempting to identify future high cost cases among Texas Medicaid COPD patients. A combination of diagnosis-based risk adjustment models and prior cost data may prove to be the most effective way to identify COPD candidates for case management.
